UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 10,855 Shares of United Therapeutics Corporation $UTHR

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 5.2% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 218,164 shares of the biotechnology company’s stock after purchasing an additional 10,855 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in United Therapeutics were worth $118,208,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Toth Financial Advisory Corp boosted its stake in shares of United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors bought a new position in United Therapeutics during the 2nd quarter valued at about $30,000. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics in the fourth quarter valued at about $31,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

UTHR stock opened at $512.70 on Wednesday. The company has a 50 day moving average price of $529.27 and a 200 day moving average price of $539.68. United Therapeutics Corporation has a fifty-two week low of $375.61 and a fifty-two week high of $609.35. The stock has a market capitalization of $21.99 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 2.55 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company earned $6.41 EPS. As a group, equities analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on UTHR shares. Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. increased their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,311,581.28. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $549.15, for a total value of $5,216,925.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,247,713.95. This represents a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 414,075 shares of company stock worth $221,222,045 in the last ninety days. 8.60% of the stock is currently owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.